arrow
G

Gavin Marx

sydney adventist hospital
H指数:35
被引数:6,201

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial

单次或多次分割立体定向消融体部放疗后联合阿替利珠单抗治疗晚期三阴性乳腺癌:一项随机II期临床试验

2026-07-270
OA
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

ALKTERNATE: 一项在ALK阳性NSCLC中交替使用氯拉替尼和克唑替尼的初步研究

2024-09-010
OA
Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
2023-10-010
OAAI
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

对照试验的最终结果: 降低HER2-positive早期乳腺癌患者来那替尼相关腹泻的发生率和严重程度的策略

BREAST
IF7.9
2023-02-0111
OAAI
Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA)

帕妥珠单抗在澳大利亚HER2-positive非转移性乳腺癌新辅助治疗中的研究 (波斯)

2022-08-253
PRE
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

脂质组学和遗传畸变对转移性去势抵抗性前列腺癌临床结局的联合影响

2022-03-2516
OAAI
Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+early-stage breast cancer
2022-02-152
PRE
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
2021-10-0129
OAAI
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

恩杂鲁胺和雄激素剥夺疗法治疗异时转移性激素敏感性前列腺癌男性的总生存期

2021-09-0133
PREAI
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

HER2-positive早期乳腺癌患者对来那替尼的耐受性改善: 对照试验

2020-09-0178
OAAI
CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane
2020-02-150
PRE